Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02779231 · ClinicalTrials.gov registry record · NA
Text Messages and Blood Pressure Control
A NA study, sponsored by Linnea Polgreen.
- Completed
- Registry status
- NA
- Development phase
- 430
- Enrollment target
NCT02779231 is a NA study that has completed, run by Linnea Polgreen. The registered enrollment target is 430 participants.
The verdict
NCT02779231, a NA study, has completed, sponsored by Linnea Polgreen.
- COMPLETED
- Registry status
- NA
- Development phase
- 430 participants
- Enrollment target
Study Summary
Hypertension remains one of the most important preventable contributors to disease and death. It is the most common risk factor for strokes and myocardial infarctions in the U.S., and is associated with the greatest attributable risk for mortality among all modifiable risk factors for cardiovascular events. Over 50 million people are living with hypertension in the United States, and hypertension is one of the most common reasons for visits to a healthcare provider. Abundant evidence from randomized controlled trials has shown benefit of antihypertensive drug treatment in reducing important health outcomes in persons with hypertension. Yet, approximately 20% of U.S. adults are unaware that they have the disease. Hypertension is more difficult to diagnose than other common medical illnesses. In most cases, hypertension is asymptomatic; and accordingly patients do not seek care for it as they do for other common symptomatic illness. Patients are frequently diagnosed after presenting with end organ disease (e.g., myocardial infarctions, congestive heart failure, strokes, or renal failure). Another complicating aspect related to diagnosing uncontrolled hypertension is that multiple blood pressure measurements are needed to establish a diagnosis. Blood pressure readings can be falsely elevated in clinic due to the presence of an observer or the clinical surrounding (e.g., white coat hypertension). Even if an elevated blood pressure reading is identified in a clinic setting, more readings are needed in order to make it possible for physicians to decide about the next appropriate medical intervention. This need for multiple BP measurements over time often delays both initiating and modifying medical therapy for uncontrolled hypertension. Having patients take their BP at home facilitates the more timely diagnosis of uncontrolled hypertension by reducing diagnostic uncertainty. In fact, home measurements are better diagnostic indicators of stroke and cardiovascular mortali
Interventions
- OTHER Bi-directional texting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02779231
The ClinicalTrials.gov registry entry for NCT02779231 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 430 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Linnea Polgreen, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bi-directional texting is the first listed.
NCT02779231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02779231 about?
NCT02779231 is a clinical study titled "Text Messages and Blood Pressure Control". Hypertension remains one of the most important preventable contributors to disease and death. It is the most common risk factor for strokes and myocardial infarctions in the U.S., and is associated with the greatest attributable risk for mortality among all modifiable risk factors for cardiovascular...
What is the current status of trial NCT02779231?
This trial is currently completed. It is a NA study. The enrollment target is 430 participants. The study started on 2015-09. Estimated completion is 2017-09-30.
What interventions are being tested in trial NCT02779231?
The interventions under investigation include: Bi-directional texting (OTHER).
Who is sponsoring clinical trial NCT02779231?
This trial is sponsored by Linnea Polgreen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.